ROCKVILLE, MD and SHENZHEN, CHINA, October 14, 2022 HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases,

SHENZHEN, CHINA and ROCKVILLE, MD, August 30, 2022 — HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biotechnology company focused on the development of innovative multi-functional therapeutics to address th

SHENZHEN, CHINA and ROCKVILLE, MD, April 28, 2022 — HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biotechnology company developing drugs with multi-functional biological actions to address the complex pathophysiology of me

SHENZHEN, CHINA and ROCKVILLE, MD, March 31, 2022 — HighTide Therapeutics, Inc. (“HighTide”), a global, clinical-stage biopharmaceutical company leading the discovery and development of multi-functional drugs with synergistic effects

SHENZHEN, CHINA and ROCKVILLE, MD, February 22, 2022 — HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing treatments for chronic liver / gastrointestinal diseases and metabolic disorders

SHENZHEN, CHINA and ROCKVILLE, MD, January 6, 2022 — HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases,